The FDA approved the first treatment for group of progressive interstitial lung diseases
On Mar. 9, 2020, the FDA approved Boehringer Ingelheim’s Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first FDA-approved treatment for this group of fibrosing lung diseases that worsen over time.
Tags:
Source: U.S. Food and Drug Administration
Credit:
